Cited by 165Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac pacing and defibrillation studies

Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy

FORLEO, GIOVANNI B., MANTICA, MASSIMO, DE LUCA, LUCIA, LEO, ROBERTO, SANTINI, LUCA, PANIGADA, STEFANIA, DE SANCTIS, VALERIO, PAPPALARDO, AUGUSTO +7 more·2009·Journal of Cardiovascular Electrophysiology

Abstract

INTRODUCTION: Atrial fibrillation (AF) and diabetes mellitus type 2 (DM2) often coexist; however, a small number of patients with DM2 undergoing catheter ablation (CA) of AF have been included in previous studies. The aim of this study was to evaluate safety and efficacy of ablation therapy in DM2 patients with drug refractory AF. METHODS AND RESULTS: From January 2005 to September 2006, 70 patients with a diagnosis of DM2 and paroxysmal (n = 29) or persistent (n = 41) AF were randomized to receive either pulmonary vein isolation or a new antiarrhythmic drug treatment (ADT) with a 1-year follow-up. The primary endpoint was the time to first AF recurrence. By Kaplan-Meier analysis, at the end of follow-up, 42.9% of patients in the ADT group and 80% of patients who received a single ablation procedure and were without medications were free of AF (P = 0.001). In the ablation group, a significant improvement in quality-of-life (QoL) scores as compared with ADT group was observed. Six patients in the ADT group (17.1%) developed significant adverse drug effects. Hospitalization rate during follow-up was higher in the ADT group (P = 0.01). The only complication attributable to ablation was one significant access-site hematoma. CONCLUSION: In patients with DM2, CA of AF provides significant clinical benefits over the ADT and appears to be a reasonable approach regarding feasibility, effectiveness, and low procedural risk.

Integrity signals

Registry

Crossref · 10.1111/j.1540-8167.2008.01275.x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
FORLEO, G. B., MANTICA, M., DE LUCA, L., LEO, R., SANTINI, L., PANIGADA, S., DE SANCTIS, V., PAPPALARDO, A., LAURENZI, F., AVELLA, A., CASELLA, M., RUSSO, A. D., ROMEO, F., PELARGONIO, G., & TONDO, C.
Affiliations
  • Università Cattolica del Sacro Cuore (IT)
  • Istituto Clinico Sant'Ambrogio (IT)
  • University of Rome Tor Vergata (IT)
Corresponding author
TONDO, CLAUDIO
Venue
Journal of Cardiovascular Electrophysiology
Publisher
Wiley
Published
2008-12-29
Volume
20
Issue
1
Pages
22-28
ISSN
  • 1045-3873 (ISSN-L)
  • 1540-8167
OpenAlex
W2105908026
Cited by
165
References
28
Citations by year
2026: 5 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 7 · 2021: 8 · 2020: 15 · 2019: 5 · 2018: 12 · 2017: 11 · 2016: 11 · 2015: 11 · 2014: 11 · 2013: 11 · 2012: 14
FWCI
5.09
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Cardiovascular Electrophysiology (publishedVersion)
  • PubMed (publishedVersion)
  • Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
Keywords
atrial fibrillation, type 2 diabetes, catheter ablation, pulmonary vein isolation, antiarrhythmic drugs, drug-refractory atrial fibrillation, atrial fibrillation recurrence, quality of life, adverse drug reactions, hospitalization, access site hematoma
MeSH terms
Anti-Arrhythmia Agents, Atrial Fibrillation, Diabetes Mellitus, Type 2, Female, Heart Conduction System, Humans, Italy, Male, Middle Aged, Pulmonary Veins, Treatment Outcome, Catheter Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review